Related Experiment Videos
Ormond's disease
T Kovács1, I Besznyák, I Köves
1Department of Surgery, National Institute of Oncology, Budapest, Hungary.
Acta Chirurgica Hungarica
|January 1, 1995
Summary
Ormond's disease (idiopathic retroperitoneal fibrosis) management is explored. Anti-estrogen therapy showed success in halting disease progression in two patients, offering new therapeutic possibilities.
Area of Science:
- Urology
- Oncology
- Endocrinology
Background:
- Ormond's disease, also known as idiopathic retroperitoneal fibrosis (IFP), is a rare condition with potential autoimmune origins.
- Malignancy must be considered in IFP due to its low incidence and presumed autoimmune etiology.
- Accurate diagnosis and management are crucial for patient outcomes.
Observation:
- Three cases of Ormond's disease are presented, detailing their etiopathogenesis, clinical presentation, and diagnostic approaches.
- Surgical exploration and histological verification are deemed essential for all IFP cases.
- Percutaneous nephrostomy was employed in two cases, with steroid administration as an adjunctive therapy.
Findings:
- Anti-estrogen therapy, a recently recommended approach, proved successful in two patients with IFP.
- This novel therapy led to stagnation or regression of the fibrotic process.
- The authors report being the first in Hungary to utilize anti-estrogen therapy for IFP.
Implications:
- Anti-estrogen therapy represents a promising new treatment avenue for Ormond's disease, potentially improving patient prognoses.
- The findings underscore the importance of considering less conventional therapies for rare conditions.
- Further research into the role of hormonal therapies in IFP is warranted to optimize treatment strategies.